Dr. Robert Mentz, Chief of Heart Failure at Duke University and principal investigator of the HEART-FID trial, dives into the complexities of iron deficiency in heart failure. He discusses crucial diagnostic criteria and the surprising prevalence of iron deficiency among heart failure patients. The conversation highlights the significant impact of iron on quality of life, hospitalization rates, and mortality. Mentz also explores treatment options, notably the advantages of intravenous iron therapy over oral supplements, advocating for a more tailored approach to patient management.
